Louis J. Bont, MD

University Medical Centre Utrecht
Zeist, Utrecht, Netherlands

Disclosure(s): Pfizer, AstraZeneca, Sanofi, Janssen, MeMed Diagnostics, Gates Foundation, GSK, Novavax, Julius Clinical, Ablynx, Bavaria Nordic, Moderna, and MSD: Advisor/Consultant, Board Member, Grant/Research Support, Honoraria, Regular interaction with pharmaceutical & other industrial partners.Founding chairman-ReSViNET Foundation.Received minor institutional funding to UMCU

Presentation(s):

• 167 - Phase 3, Randomized, Controlled Trial Evaluating Safety, Efficacy, and Pharmacokinetics (PK) of Clesrovimab in Infants and Children at Increased Risk for Severe Respiratory Syncytial Virus (RSV) Disease

  Thursday, October 17, 2024
  2:21 PM – 2:33 PM US PT